FDA rejects Takeda/Shire candidate
Another clinical trial of TAK-721 is needed, says the US Food and Drug Administration, which has rejected the drug.
by mikkel aabenhus hemmingsen, translated by catherine brett
A new potential treatment for eosinophilic esophagitis (EoE), chronic inflammation of the esophagus, has been shot down by the FDA.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Former Shire CEO shakes up Galderma as IPO decision looms
For subscribers
Takeda boosts sales of Lundbeck-developed drug in H1 2021
For subscribers
